Simulations Plus, Inc.
NASDAQ:SLP
Overview | Financials
Company Name | Simulations Plus, Inc. |
Symbol | SLP |
Currency | USD |
Price | 27.49 |
Market Cap | 551,647,328 |
Dividend Yield | 0.49% |
52-week-range | 27.22 - 51.22 |
Industry | Health Information Services |
Sector | Healthcare |
CEO | Mr. Walter S. Woltosz M.A.S., M.S. |
Website | https://www.simulations-plus.com |
An error occurred while fetching data.
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD